Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Rocky Mountain Poison & Drug Safety, Denver Health and Hospital Authority, Denver, CO, USA.
Br J Clin Pharmacol. 2021 Apr;87(4):1676-1683. doi: 10.1111/bcp.14397. Epub 2020 Jun 21.
To estimate prevalence of last 12-month nonmedical use (NMU) of benzodiazepines and Z-drugs (the nonbenzodiazepine hypnotics zaleplon, zolpidem and zopiclone) in the UK.
Data were collected using the Non-Medical Use of Prescription Drugs survey with poststratification weighting applied to be representative of the UK population (≥16 years). Participants were questioned about whether they had nonmedically used benzodiazepines and/or Z-drugs in the last 12-months and from where they had obtained the drug (including via a prescription, or illicitly from a friend/family member, a dealer or via the internet). Additional questions were asked about last 12-month use of illicit drugs (cannabis, cocaine, 3,4-methylenedioxymethylamphetamine [MDMA], non-pharmaceutical amphetamine, crack cocaine and/or heroin).
The study included 10 006 eligible participants representing approximately 52 927 000 UK adults. The estimated prevalence of past 12-month NMU of any benzodiazepine and/or Z-drug was 1.2% (95% confidence interval: 1.0-1.5) corresponding to approximately 635 000 adults; amongst this group only an estimated 4.6% (1.2-8.0) had NMU of both a benzodiazepine and a Z-drug. The highest prevalence of NMU for only Z-drugs was among those who had used heroin in the last 12-months (5.4%, 2.7-10.5), whilst the highest prevalence of NMU for only benzodiazepines was among those who had used illicit stimulants in the last 12-months: cocaine (5.9%, 3.8-8.9), amphetamine (5.6%, 3.1-10.0) and MDMA (5.2%, 3.1-8.8). The drug non-medically used was more commonly acquired without than with a prescription for both only benzodiazepines (70.2%, 59.4-81.1 compared to 51.3%, 41.5-64.6) and only Z-drugs (75.6%, 61.6-89.7 compared to 33.9%, 16.9-51.0).
There is little overlap between benzodiazepine and Z-drug NMU suggesting distinct nonmedical use of the drugs; future studies need to explore whether this relates to personal preference, drug availability or other factors. A significant proportion are acquiring these drugs for NMU without a prescription, so without guidance and monitoring from a medical practitioner. While the dangers of mixing benzodiazepines and heroin/other opioids are well documented, there is a paucity of data regarding concomitant NMU of benzodiazepines and stimulant drugs, or NMU of Z-drugs and opioids, and, given the prevalence of these combinations, this requires further investigation.
估计英国过去 12 个月非医疗使用苯二氮䓬类药物和 Z 类药物(非苯二氮䓬类催眠药扎来普隆、唑吡坦和佐匹克隆)的流行率。
使用非医疗使用处方药物调查收集数据,并进行后分层加权,以代表英国人口(≥16 岁)。参与者被问及他们是否在过去 12 个月中非医疗使用过苯二氮䓬类药物和/或 Z 类药物,以及他们从何处获得药物(包括通过处方,或从朋友/家人、经销商或通过互联网非法获得)。还询问了过去 12 个月中非法药物(大麻、可卡因、3,4-亚甲二氧基甲基苯丙胺[MDMA]、非处方苯丙胺、快克可卡因和/或海洛因)的使用情况。
该研究纳入了 10006 名符合条件的参与者,代表了大约 52927000 名英国成年人。过去 12 个月非医疗使用任何苯二氮䓬类药物和/或 Z 类药物的估计流行率为 1.2%(95%置信区间:1.0-1.5),对应约 635000 名成年人;在这一群体中,只有估计 4.6%(1.2-8.0)的人同时非医疗使用了苯二氮䓬类药物和 Z 类药物。仅使用 Z 类药物的非医疗使用率最高的是过去 12 个月内使用过海洛因的人群(5.4%,2.7-10.5),而仅使用苯二氮䓬类药物的非医疗使用率最高的是过去 12 个月内使用过非法兴奋剂的人群:可卡因(5.9%,3.8-8.9)、苯丙胺(5.6%,3.1-10.0)和 MDMA(5.2%,3.1-8.8)。对于仅苯二氮䓬类药物和仅 Z 类药物,无处方而非处方获得的药物非医疗使用更为常见:分别为 70.2%(59.4-81.1)和 75.6%(61.6-89.7),而分别为 51.3%(41.5-64.6)和 33.9%(16.9-51.0)。
苯二氮䓬类药物和 Z 类药物的非医疗使用之间几乎没有重叠,这表明这些药物的非医疗使用方式不同;未来的研究需要探讨这是否与个人偏好、药物供应或其他因素有关。相当一部分人在没有处方的情况下获得这些药物用于非医疗目的,因此没有医疗从业者的指导和监测。虽然混合使用苯二氮䓬类药物和海洛因/其他阿片类药物的危险已得到充分记录,但关于同时非医疗使用苯二氮䓬类药物和兴奋剂药物或 Z 类药物和阿片类药物的数据很少,鉴于这些组合的流行率,这需要进一步调查。